These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15533448)

  • 41. Abnormal prion protein is associated with changes of plasma membranes and endocytosis in bovine spongiform encephalopathy (BSE)-affected cattle brains.
    Ersdal C; Goodsir CM; Simmons MM; McGovern G; Jeffrey M
    Neuropathol Appl Neurobiol; 2009 Jun; 35(3):259-71. PubMed ID: 19473293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
    Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The reconstitution of mammalian prion infectivity de novo.
    Baskakov IV
    FEBS J; 2007 Feb; 274(3):576-87. PubMed ID: 17288547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strain-specific effects of reducing agents on the cell-free conversion of recombinant prion protein into a protease-resistant form.
    Imamura M; Kato N; Okada H; Iwamaru Y; Shimizu Y; Mohri S; Yokoyama T
    Microbiol Immunol; 2011 Sep; 55(9):633-40. PubMed ID: 21645053
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PrP genetics in ruminant transmissible spongiform encephalopathies.
    Goldmann W
    Vet Res; 2008; 39(4):30. PubMed ID: 18284908
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient in vitro amplification of a mouse-adapted scrapie prion protein.
    Murayama Y; Yoshioka M; Yokoyama T; Iwamaru Y; Imamura M; Masujin K; Yoshiba S; Mohri S
    Neurosci Lett; 2007 Feb; 413(3):270-3. PubMed ID: 17174030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical features of PrP(d) accumulation in natural and experimental goat transmissible spongiform encephalopathies.
    Jeffrey M; Martin S; González L; Foster J; Langeveld JP; van Zijderveld FG; Grassi J; Hunter N
    J Comp Pathol; 2006; 134(2-3):171-81. PubMed ID: 16542672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
    Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
    Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regional and phenotype heterogeneity of cellular prion proteins in the human brain.
    Kuczius T; Koch R; Keyvani K; Karch H; Grassi J; Groschup MH
    Eur J Neurosci; 2007 May; 25(9):2649-55. PubMed ID: 17466020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide NMHRYPNQ of the cellular prion protein (PrP(C)) inhibits aggregation and is a potential key for understanding prion-prion interactions.
    Rehders D; Claasen B; Redecke L; Buschke A; Reibe C; Jehmlich N; von Bergen M; Betzel C; Meyer B
    J Mol Biol; 2009 Sep; 392(1):198-207. PubMed ID: 19607841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Horse prion protein NMR structure and comparisons with related variants of the mouse prion protein.
    Pérez DR; Damberger FF; Wüthrich K
    J Mol Biol; 2010 Jul; 400(2):121-8. PubMed ID: 20460128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
    Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
    Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A rapid dual staining procedure for the quantitative discrimination of prion amyloid from tissues reveals how interactions between amyloid and lipids in tissue homogenates may hinder the detection of prions.
    Hervé R; Collin R; Pinchin HE; Secker T; Keevil CW
    J Microbiol Methods; 2009 Apr; 77(1):90-7. PubMed ID: 19318058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Host and transmissible spongiform encephalopathy agent strain control glycosylation of PrP.
    Somerville RA
    J Gen Virol; 1999 Jul; 80 ( Pt 7)():1865-1872. PubMed ID: 10423157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of scrapie-associated PrP accumulation. Probing the role of glycosaminoglycans in amyloidogenesis.
    Priola SA; Caughey B
    Mol Neurobiol; 1994; 8(2-3):113-20. PubMed ID: 7999307
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accumulation of prion protein in the brain that is not associated with transmissible disease.
    Piccardo P; Manson JC; King D; Ghetti B; Barron RM
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4712-7. PubMed ID: 17360589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Infectious particles, stress, and induced prion amyloids: a unifying perspective.
    Manuelidis L
    Virulence; 2013 Jul; 4(5):373-83. PubMed ID: 23633671
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Prion Concept and Synthetic Prions.
    Legname G; Moda F
    Prog Mol Biol Transl Sci; 2017; 150():147-156. PubMed ID: 28838659
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C1q binding and complement activation by prions and amyloids.
    Sim RB; Kishore U; Villiers CL; Marche PN; Mitchell DA
    Immunobiology; 2007; 212(4-5):355-62. PubMed ID: 17544820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.